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This review focuses on the chemistry of the Stemona alkaloids,
and covers the literature from 1975 to 1998. In this period thirty-
five new Stemona alkaloids were isolated from Stemonaceae
species and had their structures elucidated. More recently, the
total syntheses of some of these alkaloids were reported. The
biological activity of some representatives has also been
evaluated.
The Stemona alkaloids represent a class of polycyclic
alkaloids with relatively complex structures which emerged
from the structural elucidation of its first representative,
tuberostemonine (2, Fig. 2) in the sixties. The chemical
investigation of Stemonaceae species was initially motivated by
their use in Chinese and Japanese folk medicine in the treatment
of respiratory diseases and as anthelmintics. However, the
biological activity of Stemonaceae species could not be
associated with any of the Stemona alkaloids.1 The last review
of this class of alkaloids covering the structural elucidation of
tuberostemonine, stenine, oxotuberostemonine, stemonine, pro-
tostemonine, stemofoline and tuberostemonine A was reported
by Götz and Strunz in 1975.1 Additionally, the physical data of
eleven representatives of this family possessing unknown
structures were included. Since then, the isolation of new
Stemona alkaloids and the elucidation of some previously
unknown structures have been described in the literature.2–25
The total syntheses of some Stemona alkaloids have also been
reported.26–35 More recently, a review with five references
concerning the synthetic studies on stenine was reported by
Haruna et al.36
This review focuses on the structural classification, isolation,
biological activity and total syntheses of this class of alkaloid.
Special attention is paid to both structural classification and
synthetic studies.
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2 Structural classification
The Stemona alkaloids are structurally characterized by the
presence of the pyrrolo[1,2-a]azepine nucleus,2 also named
perhydroazaazulene3 and 4-azaazulene4 (A, Fig. 1). After the
review by Götz and Strunz1, thirty-five new Stemona alkaloids
were reported in the literature,2–25 currently comprising a total
of forty-two structures.
Xu and coworkers have previously suggested that the
Stemona alkaloids can be separated into eight structural groups
according to the sites of connection between the basic ring and
the side chain.4 However, these authors have only specified the
maistemonine,4 tuberostemonine,22 croomine22 and proto-
stemonine23 groups. We have also classified these alkaloids
according to their structural features into five groups (stenine I,
stemoamide II, tuberostemospironine III, stemonamine IV,
tuberostemoamide V (Fig. 1)) containing the pyrrolo[1,2-
a]azepine nucleus characteristic of the majority of the Stemona
alkaloids and a miscellaneous group lacking this basic nu-
cleus.
The group denominations adopted in this review may differ
from those previously suggested by Xu and coworkers4,22,23
since we decided to consider the name of the structurally
simplest alkaloid of each group as the parent name. The name
adopted for the basic skeleton in each group was based on the
nomenclature of its members described in Chemical Abstracts.
The numbering system of the structures was based on that
described in the literature.3,4,11,12
2.1 Stenine group
The stenine group currently comprises seven members: stenine1
1, tuberostemonine1,3 2, tuberostemonine A1 3, tuberostemo-
nol3 4, didehydrotuberostemonine3 5, bisdehydroneotuber-
ostemonine22,25 6 and neotuberostemonine22,25 7 (Fig. 2),
which can be structurally represented by the tetracyclic
furo[2,3-h]pyrrolo[3,2,1-jk][1]benzazepin-10(2H)-one nucleus
(I, Fig. 1). Didehydrotuberostemonine (5) has also been named
bisdehydrotuberostemonine.22 Another stenine alkaloid named
stemonine LG was reported in the literature17 but with only
partial stereochemical assignment. Later on, Dao and cowork-
ers37 referring to this alkaloid as tuberostemonine LG, estab-
lished its structure by X-ray analysis which showed it to be
identical to neotuberostemonine (7). The absolute configuration
of stenine (1) was first established through its chemical
conversion to derivatives of tuberostemonine (2) which had its
absolute configuration revealed by X-ray diffraction analysis
(heavy-atom method)1 and later, by its asymmetric synthe-
sis30,34 (see Section 5.1). The oxidative cleavage of the C-3–C-
18 bond in tuberostemonine A (3) afforded a lactam identical to
the one obtained from tuberostemonine (2) thus revealing the
absolute configuration depicted for tuberostemonine A (3) in
Fig. 2.1 The relative configurations of tuberostemonol (4) and
neotuberostemonine (7) were established by  2D-NMR stud-
ies.3,22 The structure of didehydrotuberostemonine (5) was
identified by direct comparison of physical and chemical data
with those obtained from the oxidation products of tuber-
ostemonine (2).3
Comparison of the 1H NMR chemical shifts of bisdehy-
droneotuberostemonine (6) and didehydrotuberostemonine (5)
revealed for 6 the relative configuration represented in Fig. 2,
however the stereochemistry at C-10 was not depicted in ref. 22
but the ethyl group at C-10 was represented with b orientation
in ref. 25. Except for stenine (1), the simplest representative
alkaloid of this group, all the other members have an a-methyl-
g-butyrolactone ring attached to C-3 in the pyrrolidine ring A.
Stenine (1), tuberostemonine (2), tuberostemonine A (3),
tuberostemonol (4) and didehydrotuberostemonine (5), show
cis relationships between H-11, H-12 and the methyl group at C-
13 in the lactone ring D. Bisdehydroneotuberostemonine (6)
and neotuberostemonine (7) also display the cis relationship for
these hydrogens which, however, are disposed trans to the
methyl group at C-13. The absolute configuration at C-13 is the
same as the one proposed for the other members of this group.
Surprisingly, tuberostemonine A (3) is the only Stemona
alkaloid to display an (R)-absolute configuration at C-3 when
the a-methyl-g-butyrolactone ring is attached to this stereo-
genic center. The cis B–C and C–D ring junction is observed for
1, 2, 3 and 7 while trans stereochemistry for the A–C ring
junction is generally adopted, except for neotuberostemonine
(7). Tuberostemonol (4) is the only Stemona alkaloid to display
a hydroxy group at C-9. Oxotuberostemonine1 8 possesses a
structure closely related to the stenine group but with the
oxygen atom of the lactone ring D reallocated from C-11 to C-1,
keeping the same relative configuration. Additionally, oxo-
Fig. 1 Stemona alkaloid groups.
Fig. 2 Stemona alkaloids of the stenine group (1–7) and oxotuber-
ostemonine (8).


































tuberostemonine (8) displays a hydroxy group at C-11 and it is
the only Stemona alkaloid to display a double bond at C-9–C-
9a. Götz1 pointed out the possibility that oxotuberostemonine
(8) is an artifact formed by air oxidation of tuberostemonine (2)
since it has also been obtained from tuberostemonine oxidation
with mercuric acetate.
2.2 Stemoamide group
This group is currently represented by nine alkaloids: stemoa-
mide3 9, stemonine1,2,23 10, neostemonine23,2511, bisdehydro-
neostemonine23,25 12, protostemonine1,16,18,23 13, didehydro-
protostemonine18,23,25 14, isoprotostemonine18,23,25 15,
tuberostemoamide20,21 16 and stemoninine5,7,9 17 (Fig. 3),
which display the tricyclic 2H-furo[3,2-c]pyrrolo[1,2-a]azepine
nucleus (II, Fig. 1). Additionally, neostemodiol18 18 has been
included in the stemoamide group despite lacking ring C since
it can be associated to neostemonine (11) through dehydration
to form ring C. Neostemodiol (18) has also been named
stemodiol by the same authors.18 Some members of this group
(10, 11, 12, 13, 14 and 15) have been reported as proto-
stemonine-type alkaloids.23 Before the isolation of 11, the name
neostemonine was applied to 12,18 but after that it has been
changed to its current name bisdehydroneostemonine.23 Addi-
tionally, 12 has been depicted in ref. 25 with cis fused B and C
rings. Alkaloid 9 has been mistakenly reported as stemona-
mide31 while structures 14 and 16 have also been reported as
bisdehydroprotostemonine23,25 and stemoninoamide,20,21 re-
spectively. Lin and coworkers reported different optical rotation
values ([a]D +94 (c 0.06, MeOH)20 and [a]D 294 (c 0.06,
MeOH)21) for 16. The alkaloid represented by structure 17 was
also named stemoninoine20,21 and stemoninone.20 Stemoamide
(9) had its relative configuration obtained by NMR studies and
comparison of its 1H NMR chemical shifts and coupling
constant values with those of stemoninine (17).3 Later on the
absolute configuration of 9 was established through its
asymmetric syntheses.29,33 Stemonine (10) had its absolute
stereochemistry revealed by X-ray analysis of its hydrobromide
hemihydrate by consideration of anomalous dispersion ef-
fects.38 Neostemonine (11), bisdehydroneostemonine (12) and
tuberostemoamide (16) are represented by their relative config-
uration obtained from NMR studies and comparison of their 1H
NMR data to those of 13, 14 and 17, respectively.20,23 However,
the relative configuration at C-11 of 16 has not been
specified.20
Protostemonine (13) and stemoninine (17) had their relative
stereochemistries revealed from NMR studies9,18 while didehy-
droprotostemonine (14) had its relative configuration obtained
after comparison of its NMR data to those of protostemonine
(13).18,23 Additionally, protostemonine (13) has been pre-
viously converted to its hydrate hydrochloride and than afforded
stemonine (10) upon K2CO3 treatment or vacuum pyrolysis,1
and oxidation of 13 with Ag2O afforded 14.23 Comparison of
the NMR data of isoprotostemonine (15) and protostemonine
(13) revealed for the former alkaloid the relative configuration
represented in Fig. 3.18,23
The alkaloids 10, 13, 14, 15 and 17 display an a-methyl-g-
butyrolactone ring attached to C-3 in the pyrrolidine ring A.
Moreover, the trans ring fusion of the B–C rings, the cis
relationship between the hydrogens at C-9 and C-9a and the (S)
absolute configuration at C-10 are noteworthy stereochemical
features of this group of alkaloids. The Stemona alkaloids 11,
12, 13, 14 and 15 have a disubstituted lactone ring attached to
ring C at C-11 by a double bond as a distinct characteristic of
this group. The Stemona alkaloids 16 and 17 display an
unsaturated spirolactone ring fused at C-11. Interestingly, these
two alkaloids have an ethyl substituent at C-10 instead of the
methyl substituent found in the other members of this group.
Surprisingly, isoprotostemonine (15) has the disubstituted
lactone ring disposed with opposite geometry around the
exocyclic double bond when compared to the other members of
the group. In fact this is the only structural difference between
protostemonine (13) and isoprotostemonine (15).
2.3 Tuberostemospironine group
The tuberostemospironine group of Stemona alkaloids is
characterized by a 2H-spiro[furan-2,9A[9H]pyrrolo[1,2-a]aze-
pin]-5-one nucleus which displays a spiro g-lactone at C-9 of
the basic ring (III, Fig. 1) and comprises seven members:
tuberostemospironine3 19, croomine6,19 20, stemospironine2
21, stemotinine8 22, isostemotinine8 23, stemonidine1,8 24 and
didehydrocroomine19 25 (Fig. 4). The Stemona alkaloids 20, 22,
23 and 24 have been reported as croomine-type alkaloids.8,22
The relative configurations of alkaloids tuberostemospironine
(19), stemotinine (22), isostemotinine (23) and stemonidine
(24) were established by NMR studies3,8 while croomine6 (20)
and stemospironine2 (21) had their absolute configurations
obtained by X-ray analyses (heavy-atom method). The relative
configuration of didehydrocroomine (25) was revealed by NMR
studies and it was correlated with croomine (20) after Ag2O
oxidation.19 Croomine (20), stemospironine (21), stemotinine
Fig. 3 Stemona alkaloids of the stemoamide group and stemodiol (18).


































(22) and didehydrocroomine (25) display at C-9 an opposite
stereochemistry to that found in tuberostemospironine (19),
isostemotinine (23) and stemonidine (24). Of these seven
alkaloids, tuberostemospironine (19) is the only one which
lacks the a-methyl-g-butyrolactone ring appended to C-3 of the
pyrrolidine ring A. Curiously, stemotinine (22) and iso-
stemotinine (23) have an oxygen bridge between C-9a and C-6.
In fact these two alkaloids are the only Stemona alkaloids with
such a characteristic and they differ by the absolute configura-
tion at C-9 and C-11.
2.4 Stemonamine group
Previously reported as the maistemonine group,4 this group is
characterized by the tetracyclic 2AH,11H-spiro[1H-cyclopenta-
[b]pyrrolo[1,2-a]azepine-11,2A-furan]-5A,10-dione nucleus with
a spirolactone ring at C-12 (IV, Fig. 1) which may be found in
both absolute configurations. The stemonamine group includes
the following Stemona alkaloids: stemonamine4 26, iso-
stemonamine4 27, stemonamide4,25 28, isostemonamide4,25 29,
maistemonine4,13,16 30 and oxymaistemonine4,13,16 31 (Fig. 5).
The alkaloids 30 and 31 were first reported to display (R)-
absolute configuration at C-9a.13,16 Later on their correct
structures were revealed by conversion of 30 to 28.4 The
literature24 also reports the name protostemotinine when
referring to structure 30, despite the difference in the melting
points reported for maistemonine4 (mp 205–207 °C) and
protostemotinine24 (mp 214–246 °C). Curiously, stemonamine
(26) and isostemonamine (27) were identified as racemic
alkaloids and stemonamine (26) displayed racemic pairs of
molecules in the X-ray analysis.39 Stemonamide (28) and
isostemonamide (29) had their relative configurations estab-
lished by NMR studies.4 The relative configuration of oxy-
maistemonine (31) was obtained by comparison of its NMR
data with those for maistemonine (30).13 The configuration at
C-8 in 31 was confirmed by coupling constant value in
combination with the inspection of the Dreiding structural
model.13 Stemonamine (26) and stemonamide (28) only differ
from isostemonamine (27) and isostemonamide (29), re-
spectively, by the absolute configuration at C-12. All the
members of this group show the (S)-absolute configuration at C-
9a and the a-methyl-g-butyrolactone ring attached to C-3 is
found only in the alkaloids maistemonine (30) and oxy-
maistemonine (31).
2.5 Parvistemoline group
The parvistemoline alkaloids are characterized by the lack of
the B–C ring fusion and a hexahydro-2,6-dimethyl-5-ox-
ofuro[3,2-b]furan-3-yl moiety attached to C-9 in the pyrrolo
[1,2-a]azepine nucleus (V, Fig. 1). This group comprises the
alkaloids parvistemoline11 32, parvistemonine10,15 33 and
didehydroparvistemonine11 34 (Fig. 6). Parvistemonine (33)
and didehydroparvistemonine (34) have a g-lactone ring
positioned at C-3. The structures of these alkaloids were
established by IR, MS and NMR studies but only parvistemo-
nine (33) had its relative configuration unambigously depicted
in the literature.10
2.6 Miscellaneous group
The miscellaneous group includes eight Stemona alkaloids:
stemofoline1,2,12 35, oxystemofoline12 36, methoxystemofo-
line12 37, parvistemoninine15 38, parvistemoninol15 39, tuber-
ostemonone3,14 40, tuberostemoninol20,21 41 and parvistemoa-
mide11,15 42 (Fig. 7). The relative configurations at C-8, C-9a
and C-10 of parvistemoamide (42) are not unambiguously
depicted in ref. 11 but the same group described in ref. 15 the
relative stereochemistry shown in Fig. 7. Stemofoline (35) had
its absolute configuration established by X-ray analysis of its
hydrobromide monohydrate (heavy-atom method)40 while the
alkaloids oxystemofoline12 (36), methoxystemofoline12 (37)
and parvistemoamide11 (42) had their relative configurations
obtained by 2D-NMR studies. Tuberostemonone14 (40) and
tuberostemoninol20 (41) are represented by their relative
configuration which were established by X-ray analyses.
Fig. 4 Stemona alkaloids of the tuberostemospironine group.
Fig. 5 Stemona alkaloids of the stemonamine group.
Fig. 6 Stemona alkaloids of the parvistemoline group.


































Although the members of this group lack the pyrrolo[1,2-
a]azepine nucleus, they still keep in their structure some
characteristic fragments present in the members of the other
groups. The alkaloids 35–37 and 38–39 are structurally the most
complex Stemona alkaloids and differ from each other by the
nature of the substituent attached to the side chain at C-3. The
removal of the C-2–oxygen and C-8–oxygen bonds, the C-3–C-
7 bond and the side chain at C-3 in 35–37 formally leads to the
stemoamide alkaloid neostemonine (11) (Fig. 3). Tuber-
ostemonone (40) can be associated with the stenine group as a
product of their oxidative cleavage of the C-1–C-9a bond.
Unlike the members of that group, 40 shows a trans relationship
between the C-5 and C-9 hydrogens and between the hydrogen
at C-11 and the ethyl group at C-10.
As for 40, tuberostemoninol (41) can also be associated with
the stenine group by the oxidative cleavage of the C-1–C-9a
bond (stenine group numbering) to form a dicarbonylic system,
followed by the nucleophilic attack of the enol form of the
carbonyl group at C-9 to the carbonyl group at C-1. The
structurally simplest Stemona alkaloid, parvistemoamide (42)
may be associated with the members of stemoamide group
(Fig. 3) by the nucleophilic attack of the nitrogen atom of 42 to
a keto group at C-9a followed by reduction at this carbon.
3 Natural sources
3.1 Stemonaceae family
The family Stemonaceae (order Dioscoreales) is today the only
source of the Stemona alkaloids. This family is a monocotyle-
don described by Engler in 1887.41 Although Dahlgren41
reported for this family the genera Stemona, Croomia, Sticho-
neuron and Pentastemona, Duyfjes,42 and later Bouman,43
found evidence which allowed them to separate the genus
Pentastemona into a new family, Pentastemonaceae. Stemona,
earlier named Roxburghia, is the most representative genus of
the family Stemonaceae, occurring from southern Asia and
Malaysia to northern Australia. The literature reports the
existence of 25 species for this genus. The genus Croomia
comprises three species and occurs in Atlantic North America
and Japan. The third genus, Stichoneuron, is composed of two
species distributed in eastern Asia.41
3.2 Phytochemical studies
Although the Stemonaceae family comprises more than 30
species, the phytochemical investigation of this family is
restricted to only eight of them, most belonging to the genus
Stemona (Table 1). As far as we know, no phytochemical study
has been reported so far for the genus Stichoneuron. Ren-sheng
Xu and coworkers initiated an extensive investigation of some
Fig. 7 Stemona alkaloids of the miscellaneous group.
Table 1 Stemona alkaloids isolated from Stemonaceae species
Stemonaceae
species Stemona alkaloid Reference
S. tuberosa Stenine 1 1
Tuberostemonine 2 1, 3
Tuberostemonol 4 3
Didehydrotuberostemonine 5 3
Bisdehydroneotuberostemonine 6 22, 25
Neotuberostemonine 7 22, 25
Oxotuberostemonine 8 1
Stemoamide 9 3




Tuberostemonone 40 3, 14
Tuberostemoninol 41 20, 21
S. japonica Stemonine 10 1, 23
Neostemonine 11 23, 25
Bisdehydroneostemonine 12 18, 23, 25
Protostemonine 13 1, 18, 23
Didehydroprotostemonine 14 18, 23, 25





Stemonamide 28 4, 25
Isostemonamide 29 4, 25
Maistemonine (Protostemotinine) 30 4, 18
Neostemodiol (Stemodiol) 18 18
Stemofoline 35 1, 2
S. parviflora Parvistemoline 32 11
Parvistemonine 33 10, 15
Didehydroparvistemonine 34 11
Stemofoline 35 12




Parvistemoamide 42 11, 15
S. sessilifolia Tuberostemonine 2 1
Tuberostemonine A 3 1
Stemoninine 17 9
Protostemotinine (Maistemonine) 30 24
S. mairei Protostemonine 13 16
Maistemonine (Protostemotinine) 30 13, 16
Oxymaistemonine 31 13, 16
Stemona sp. Protostemonine 13 1
Stemoninine 17 5, 7
C. japonica Croomine 20 19
Didehydrocroomine 25 19
C. heterosepala Croomine 20 6


































Stemona species in the early 80’s leading to the isolation and
structural elucidation of most of the currently known Stemona
alkaloids.25 Most of the phytochemical studies of this family
were restricted to the roots although studies of leaves,2 stems2
and rhizomes1,6,24 have also been reported. Due to their
complex structures, most of the Stemona alkaloids had their
structure elucidated by crystallographic analyses.2,6,14,20,37–40
4 Biological activities
The popular use of Stemonaceae extracts as insecticides,
vermifuges and in the treatment of respiratory diseases in China
and Japan is described in the literature.1,2,23,44 The water
extracts obtained from the roots of some Stemonaceae species
were widely used in China against human and cattle parasites,
agricultural pests and as domestic insecticides.2 The basic
methanolic extracts obtained from fresh leaves of Stemona
japonica showed strong insecticidal activity against silk worm
larvae.2 The crude extracts of Stemonaceae species have also
shown antitubercular and antitussive activities.44 These bio-
logical activities motivated the chemical investigation of
Stemonaceae species in order to find their active principles.
Tuberostemonine (2) (Fig. 2) was the first Stemona alkaloid to
have its biological activity tested. Although the initial results
did not show activity against Hymenolepis nana and Nemato-
spiroides dubius,1 its anthelminthic activity was detected when
tested against Angiostrongylus cantonensis, Dipylidium cani-
num and Fasciola hepatica with an effect on the motility of
these helminthic worms. These results motivated Shinozaki and
Ishida to test the action of this alkaloid on the neuromuscular
transmission in crayfish which is considered a model for
studying the mechanism of drug action in the mammalian
central nervous system. The results obtained in the tests
demonstrated that tuberostemonine depressed glutamate-in-
duced responses at similar concentrations to those of established
glutamate inhibitors.44 The insecticidal activity of stemonine
(10) (Fig. 3), stemospironine (21) (Fig. 4) and stemofoline (35)
(Fig. 7) against the fourth instar Bombyx mori (silkworm larvae)
is reported in the literature.2 Alkaloid 35 showed a very potent
activity against the larvae, being 104 times more toxic than
alkaloid 21. Stemonine (10) and stemospironine (21) showed
similar moderate results. Otherwise, these three alkaloids
showed no activity against the fifth instar larvae of cabbage
army worm (Mamestra brassicae). Neostemonine (11) and
isoprotostemonine (15) (Fig. 3) had their antifeeding activity
tested against last-instar larvae of Spodoptera litura but with
little activity.23 No antimicrobial or antiviral activities were
detected for these two alkaloids.23 As far as we know no other
Stemona alkaloid has had its biological activity tested.
5 Synthetic sources
The complex molecular architecture of the Stemona alkaloids
has stimulated the synthetic work on this family of natural
products. In this section only the approaches which culminated
in the total synthesis of a member of this family will be
discussed, although several studies have also appeared directed
towards the assembly of their major structural motifs.45–53
5.1 Stenine group
Stenine (1) is the only representative of this group of Stemona
alkaloids which has so far yielded to total synthesis. Chen and
Hart first described the total synthesis of racemic stenine (1) in
1990.27,28 The construction of the advanced intermediate 50
containing the ACD substructure was initiated with an intra-
molecular Diels–Alder reaction (43 ? 44, Scheme 1) followed
by a Curtius rearrangement (45 ? 46) which set the stage for
ring A formation (Scheme 1). Claisen–Eschenmoser rearrange-
ment (48 ? 49) and iodolactonization completed the assembly
of tricyclic intermediate 50. Ring B was finally put in place after
homologation of the side chain at C-9 and intramolecular lactam
formation (50 ? 51). The first total synthesis of racemic stenine
(1) was completed in 25 steps from 43 and 7.2% overall yield
after the conversion of the allylic residue at C-10 to the requisite
ethyl substituent and the adjustment of the oxidation level at
ring B.
Wipf and coworkers30 have reported the first asymmetric
synthesis of (2)-stenine (1) based on an efficient preparation of
a hydroindolenone intermediate through the oxidation of N-
benzyloxycarbonyltyrosine with hypervalent iodine, followed
by the reduction of the corresponding p-allylpalladium inter-
mediate (52 ? 54, Scheme 2). The stereogenic center at C-9
was established through enolate alkylation and the acetamido
side chain at C-12 by a Claisen–Eschenmoser rearrangement
(54 ? 55). Selective cleavage of the terminal olefin was
accomplished with Sharpless asymmetric dihydroxylation fol-
Scheme 1 Reagents: (a) Et2AlCl, CHCl3, 80 °C (67%); (b) H2NNH2, H2O, MeOH, reflux (87%); (c) MeI, K2CO3, MeOH, reflux (100%); (d) AcCl, 0 °C
? rt (100%); (e) mesitylene, reflux; then, MeOH, reflux (94%); (f) 9-BBN, THF, 0 °C ? rt; then NaBO3·4H2O, H2O, rt (95%); (g) MsCl, Et3N, CH2Cl2,
0 °C ? rt (100%); (h) MeLi, THF, 278 °C ? rt (83%); (i) Jones’ reagent, acetone, 0 °C (83%); (j) I2, THF–Et2O, aq. NaHCO3, 0 °C ? rt (95%); (k) DBU,
toluene, reflux (98%); (l) 2-methylpropan-2-ol, MeOH, NaBH4, 50 °C (100%); (m) TBSCl, Et3N, CH2Cl2, DMAP, rt (97%); (n) MeC(OMe)2NMe2, xylenes,
reflux (93%); (o) I2 THF, H2O, rt (75%); (p) CH2CHCH2SnBu3, AIBN, C6H6, reflux (83%); (q) LDA, MeI, THF, HMPA, 278 °C (87%); (r) DMSO,
(COCl)2, CH2Cl2; 278 °C then Et3N (99%); (s) Ph3PNCHCO2Et, CHCl3, reflux (91%); (t) Red-Al, CuBr, THF, butan-2-ol, 278 °C ?220 °C (85%); (u)
Me3SiI, CHCl3, rt (94%); (v) mesitylene, reflux (91%); (w) OsO4 (cat.), NaIO4 THF, H2O, rt (84%); (x) HSCH2CH2SH, SiO2–SOCl2, CH2Cl2, rt (100%);
(y) (p-MeOC6H4PS2)2, CH2Cl2, rt (100%); (z) W-2 Raney-Ni, EtOH, reflux (80%).


































lowed by sodium periodate cleavage of the corresponding diol.
Reductive decarboxylation (56 ? 57) set the stage for
iodolactonization, followed by a stereoselective radical allyla-
tion (57 ? 58) and enolate alkylation, a sequence of events
which resembles the approach by Chen and Hart.27,28 The
azepine ring B was formed through intramolecular nitrogen
Scheme 2 Reagents: (a) PhI(OAc)2, MeOH, NaHCO3, 23 °C (54%); (b) Bz2O, CH2Cl2, pyridine, DMAP, reflux (90%); (c) NaBH4, CeCl3·7H2O, MeOH,
THF, rt (99%); (d) Pd2(dba)3·CHCl3, THF, nBu3P, HCO2H, Et3N, 60 °C (68%); (e) TPAP (cat.), NMO, CH2Cl2, MS 4 Å, 0 °C ? rt (90%); (f) KHMDS,
toluene, 280 °C; then, CH2CH(CH2)3OTf, THF, 260 °C (51%); (g) NaBH4, CeCl3·7H2O, THF, MeOH, 40 °C (91%); (h) MeC(OMe)2NMe2, xylenes, reflux
(85%); (i) AD-mix-b, tert-BuOH, H2O, 5 °C; then, tert-BuOH, H2O, NaIO4, rt (82%); (j) NaBH4, THF, MeOH (93%); (k) TIPSCl, imidazole, 4-DMAP (cat.),
CH2Cl2, rt (100%); (l) LiOH, THF, MeOH, H2O, 40 °C (90%); (m) PhOP(O)Cl2, C6H5SeH, Et3N, THF, 0 °C ? 22 °C; (n) nBu3SnH, AIBN (cat.), xylenes,
130 °C (79%, 2 steps); (o) I2, THF, pH 5.5, 21 °C (85%); (p) CH2CHCH2SnBu3, AIBN (cat.), 80 °C (90%); (q) LDA, THF, HMPA, MeI, 278 °C (87%);
(r) OsO4 (cat.), NaIO4, THF, H2O, tert-BuOH, 0 °C ? 21 °C; (s) NaBH4, THF, MeOH, 240 °C (63%, 2 steps); (t) o-(NO2)PhSeCN, nBu3P, THF, 0 °C;
then, H2O2, THF, 21 °C (87%); (u) HF, CH3CN, 0 °C; (v) Dess–Martin periodinane, CH2Cl2, 21 °C; then, THF, 2-methylbut-2-ene, NaClO2, aq. Na2HPO4,
0 °C; (w) H2, Pd(OH)2/C, MeOH, 21 °C; (x) C6F5P(O)Ph2, CH2Cl2, 21 °C (71%, 4 steps); (y) (p-MeOC6H4PS2)2, CH2Cl2, 21 °C (93%); (z) Raney-Ni, EtOH,
21 °C (78%).
Scheme 3 Reagents: (a) nBuLi, THF, 225 °C; then, (E,E)-MPMO(CH2)4CHNCH–CHNCH–CH2Cl, HMPA, 278 °C ? rt; (b) pTsOH, H2O, MeOH, THF,
rt (68%, 2 steps); (c) pyr·SO3, DMSO, Et3N, CH2Cl2, 0 °C ? rt (85%); (d) A, Et3N, LiCl, THF, 0 °C ? rt (90%); (e) Me2AlCl, CH2Cl2, 220 °C (85%);
(f) AgNO3, N-chlorosuccinimide, CH3CN–H2O, 0 °C (80%); (g) LiSEt, THF, 0 °C (91%); (h) Et3SiH, 10% Pd/C, acetone, 0 °C ? rt (100%); (i) NaClO2,
NaH2PO4, 2-methylbut-2-ene, tert-BuOH, H2O, 0 °C ? rt (100%); (j) (PhO)2P(O)N3, DMF, Et3N, 60 °C; (k) MeOH, CuCl (cat.), rt (82%, 2 steps); (l)
TMSCl, NaI, CH3CN, Et3N, 50 °C; (m) MCPBA, hexane, CH2Cl2, 215 °C ? rt; (n) H5IO6, THF, H2O, rt; then, I2, NaHCO3, rt (50%, 3 steps); (o) CSA,
CH(OMe)3, MeOH, CH2Cl2, rt (90%); (p) CH2NCHCH2SnBu3, AIBN (cat.), toluene, 80 °C (80%); (q) LDA, THF, HMPA, 278 °C; then, MeI, 278 °C
(73%); (r) Et3SiH, BF3·OEt2, CH3CN, 0 °C (82%); (s) OsO4 (cat.), NaIO4, THF, H2O, rt (75%); (t) HSCH2CH2SH, BF3·OEt2, CH2Cl2, 215 °C (81%); (u)
W2-Raney-Ni, EtOH, reflux (85%); (v) MsCl, Et3N, CH2Cl2, 0 °C (88%); (w) NaI, acetone, reflux (98%); (x) TMSI, CH2Cl2, rt; (y) CH3CN, reflux (70%,
2 steps).


































acylation and the total synthesis was completed by the reduction
of lactam 60 to afford (2)-1 in 26 steps from Cbz-tyrosine (52)
and ca. 1.0% yield.
An asymmetric intramolecular Diels–Alder reaction was
employed by Morimoto and coworkers34 to construct the
bicyclic ketone 63 with four stereogenic centers correctly
assembled for the synthesis of (2)-1 and which was later on
converted to the tricyclic key intermediate 66 containing the
ACD rings after a modified Curtius rearrangement (64 ? 65,
Scheme 3), iodolactonization (65 ? 66), radical allylation and
methylation at C-11 (66 ? 67). The synthesis of (2)-1 was
completed in 24 steps from dithiane 61 and ca. 2% overall yield
after construction of ring B through an intramolecular nitrogen
alkylation (68 ? 1).
5.2 Stemoamide group
The tricyclic alkaloid stemoamide (9) is a typical representative
of this group of Stemona alkaloids and it has been synthesized
several times over the last few years, including some very
efficient approaches. Williams and coworkers29 succeeded in
preparing (2)-stemoamide (9) starting from commercially
available methyl (R)-3-hydroxy-2-methylpropionate which was
homologated and coupled with (S)-4-benzyloxazolidin-2-one to
afford chiral imide 69 (7 steps and 85% overall yield). An
asymmetric boron aldol reaction with 4-benzyloxybutanal
installed the stereogenic centers at C-8 and C-9 (70, Scheme 4).
The correct stereochemistry at C-9a was established after chain
elongation, reduction with lithium triethylborohydride (ex-
clusively from the carbonyl si face), mesylation (70 ? 71) and
methanesulfonate displacement with sodium azide which
proceeded with inversion of configuration (71 ? 72). At this
point all the carbons and the stereogenic centers of (2)-stemoa-
mide (9) were in place and the remaining steps were dedicated
to the formation of rings A, B and C and functional group
interconversions (Scheme 4). The first total synthesis of
(2)-stemoamide was then completed in 25 steps from (R)-
methyl-3-hydroxy-2-methylpropionate and 5.6% overall yield.
Kohno and Narasaka31 devised a short synthesis of (±)-ste-
moamide (9), mistakenly designated as (±)-stemonamide by
these authors, by applying the oxidative coupling reaction of
2-tributylstannyl-N-Boc-pyrrolidine with silyl enol ethers. The
key intermediate 77 was produced in 65% yield as a mixture of
stereoisomers which led to a separable mixture of diastereoi-
somers (78a+78b = 4+1) upon hydrogenation of the acetylenic
bond. The formation of 77 is rationalized through the addition
of silyl enol ether 76 (E+Z = 1+1) to an intermediate N-
acyliminium ion derived from N-Boc-2-tributylstannylpyrroli-
dine (Scheme 5). The stereogenic center at C-8 was established
after NaBH4 reduction of 78a which afforded g-lactone 79 in
59% yield. The alcohol with the wrong stereochemistry at C-8
was also obtained in 25% yield and it was converted to 79
through a 3-step sequence. In the final steps of the synthesis,
ring B was formed by intramolecular nitrogen alkylation and the
correct stereochemistry at C-10 was established by ster-
eoselective methylation of the lithium enolate of the g-lactone.
This concise approach required 12 steps from 5-benzyloxypent-
3-yn-2-one and provided (±)-stemoamide (9) in ca. 2% overall
yield.
A concise and efficient approach to (2)-stemoamide (9)
based on an intramolecular enyne metathesis was developed by
Kinoshita and Mori.33 Starting from lactam 81, prepared from
(2)-pyroglutamic acid, the acetylene 82 was obtained in 5 steps
and 50% overall yield (Scheme 6). The construction of ring B
was efficiently accomplished by enyne metathesis (87% yield)
using catalytic amount of Grubb’s catalyst (82 ? 83,
Scheme 6). Reduction to the saturated ester, followed by
bromolactonization of the mixture of epimeric carboxylic acids,
afforded unsaturated lactone 85 (31% yield) and the corre-
sponding bromolactone 84 (21% yield) which could be
converted to 85 (50% yield) by treatment with Et3N. The correct
stereochemistry at C-10 was established by reduction of 85 with
NaBH4 in the presence of NiCl2•6H2O in methanol to give
(2)-stemoamide (9), in 14 steps from (2)-pyroglutamic acid
and 9% overall yield.
By far the most concise and efficient approach to (±)-stemo-
amide (9) was developed by Jacobi and Lee35 and featured an
intramolecular Diels–Alder–retro Diels–Alder cycloaddition
between the 2-methoxyoxazole and acetylenic moieties in 89
followed by hydrolysis to set the correct relative configuration
at C-8 and C-9a (89 ? 90, Scheme 7). The stereochemistry at
C-9 and C-10 was established after nickel boride reduction of
the unsaturated butyrolactone ring and epimerization at C-10 to
afford (±)-stemoamide (9) in 73% yield, together with its
epimer at C-9 and C-10. Overall the total synthesis of
(±)-stemoamide (9) was achieved in 7 steps from 4-chlor-
obutyryl chloride (86) and 20% overall yield.
5.3 Tuberostemospironine group
(+)-Croomine (20), a prototypical example of the tuber-
ostemospironine group, was the first Stemona alkaloid to yield
to total synthesis. In 1989, Williams and coworkers26 disclosed
its total synthesis featuring an intermolecular Staudinger
reaction followed by an iodoamination step to construct the
Scheme 4 Reagents: (a) n-Bu2BOTf, CH2Cl2, Et3N, 278 °C ? 0 °C;
then, 4-benzyloxybutanal, 278 °C ? 0 °C (88%); (b) aq. HF, CH3CN, rt;
sat. aq. NaHCO3, K2CO3 (82%); (c) TBDMSOTf, collidine, CH2Cl2,
278 °C ? rt (97%); (d) 4-iodobut-1-ene, tert-BuLi, Et2O, 2100 °C; then,
TBDMSOTf, collidine, 278 °C ? rt (78%); (e) LiEt3BH, THF, 278 °C ?
rt (91%); (f) MsCl, pyridine, rt (96%); (g) NaN3, HMPA, rt; (h) O3, CH2Cl2,
MeOH, 278 °C; then, Me2S, 278 °C ? rt (49%, 2 steps); (i) NaClO2,
NaH2PO4•H2O, CH3CN, tert-BuOH, H2O, 2-methylbut-2-ene, 0 °C; (j)
CH2N2, Et2O, 0 °C (96%, 2 steps); (k) PPh3, THF, H2O, reflux (87%); (l)
H2, 10% Pd/C, EtOH; (m) MsCl, pyridine, rt; (n) NaH, THF, rt (71%, 3
steps); (o) HF·Et3N, CH3CN, rt (63%); (p) Dess–Martin periodinane,
pyridine, CH2Cl2, rt; (q) TBAF, THF, rt (94%, 2 steps); (r) PDC, CH2Cl2,
reflux (80%).


































pyrrolo[1,2-a]azepine nucleus and the g-butyrolactone ring
attached at C-3 (Scheme 8). As in the total synthesis of
(2)-stemoamide by the same group,29 Williams and coworkers
started with methyl (S)-2-methyl-3-hydroxypropionate which
was converted to acetylene 91 after 4 steps and 72% overall
yield. Sharpless asymmetric epoxidation of (E)-trisubstituted
allylic alcohol 93 and a two-carbon homologation of the
corresponding aldehyde provided epoxide 94 which set the
stage for the regioselective epoxide opening with lithium azide
(94 ? 95, Scheme 8). Chain homologation (95 ? 96) and g-
lactone formation (96 ? 97) was followed by ring B formation
through an intramolecular Staudinger reaction (97 ? 98). Rings
A and D were formed in a single step by iodoamination of
bicyclic intermediate 98, an impressive transformation which
also set the correct stereochemistry at C-3 and C-14, and yielded
(+)-croomine (20) in 25% yield from 98 which was recovered in
50–60% yield. The first total synthesis of (+)-croomine (20) was
carried out in 26 steps and about 0.5% overall yield from methyl
(S)-2-methyl-3-hydroxypropionate.
A shorter and more efficient route to (+)-croomine (20) was
devised by Martin and Barr32 who employed the vinylogous
Mannich addition of 2-silyloxyfuran 100 to a chiral N-
acyliminium ion derived from (S)-pyroglutamic acid to connect
rings A and C and to set the correct stereochemistries at C-9 and
C-9a (100 ? 101, Scheme 9). The stereochemistry at C-11 was
set after hydrogenation of the double bond in ring C (101 ?
102), probably directed by the basic nitrogen of the pyrrolidine
ring and ring B was put in place through an intramolecular
nitrogen alkylation (102 ? 103). The thermally unstable acid
chloride from intermediate 103 gave rise to the corresponding
iminium ion which was trapped with 2-triisopropylsilyloxy-
3-methylfuran. This second vinylogous Mannich transforma-
tion (103 ? 104) afforded a 47% combined yield of the desired
isomer 104 and its C-14 epimer (2+1 ratio). The desired adduct
104 was submitted to a stereoselective hydrogenation to afford
(+)-croomine (20) in 9 steps and approximately 5% overall
yield from 3-methylfuran-2(5H)-one.
6 Conclusion
Since the publication of the last review on the chemistry of the
Stemona alkaloids in 1975 the body of information about this
family of alkaloids has grown steadily.
From a few representatives with defined structure (stenine
(1), tuberostemonine (2), tuberostemonine A (3), oxotuber-
ostemonine (8), stemonine (10), protostemonine (13) and
stemofoline (35)) known at that time, 35 new representatives
were isolated and had their structures elucidated.
Croomine (20), stemospironine (21), stemonamine (26),
isostemonamine (27), tuberostemonone (39) and tuberostemo-
ninol (40) had their structures established by X-ray analyses
which also provided the absolute configuration for croomine
(20) and stemospironine (21). Interestingly, stemonamine (26)
and isostemonamine (27) were isolated in racemic form.
For the other alkaloids of this family isolated in the period
covered in this review, structural evidence was provided mainly
by NMR studies.
Scheme 5 Reagents: (a) TBSCl, Et3N, NaI, CH3CN, 50 °C (92%); (b)
tert-butyl-2-(tributylstannyl)acetate, TBACN, EtCN, K2CO3, MS 4 Å, 0 °C
(85%); (c) TBSCl, Et3N, NaI, CH3CN, 50 °C (60%); (d) 1-(tert-
butoxycarbonyl)-2-(tributylstannyl)pyrrolidine, CAN, MS 4 Å, EtCN,
245 °C (65%); (e) H2, 10% Pd/C, MeOH, rt (90%, 78a : 78b = 4:1); (f)
NaBH4, THF, MeOH, rt (59%); (g) 10% Pd/C, MeOH, HCO2H, rt (89%);
(h) MsCl, Et3N, CH2Cl2, rt (96%); (i) RuO2 (cat.), NaIO4, AcOEt, H2O, rt
(60%); (j) 1 M HCl–AcOEt, rt (89%); (k) NaH, THF, rt (62%); (l) LDA,
THF, 278 °C; then, MeI, 278 °C ? rt (59%).
Scheme 6 Reagents: (a) NaH, DMF, 5-bromopent-1-ene (89%); (b)
TsOH, MeOH (91%); (c) (COCl)2, DMSO, Et3N; (d) CBr4, Ph3P (87%, 2
steps); (e) n-BuLi, THF, 298 °C (72%); (f) LDA, HMPA, THF, ClCO2Me,
298 °C (68%); (g) Cl2Ru[P(C6H11)3]2CHPh, CH2Cl2, rt (87%); (h) NaBH4,
MeOH (85%); (i) NaOH, MeOH, H2O; (j) CuBr2 on Al2O3 (84, 25% and 85,
31%); (k) Et3N, rt (50%); (l) NaBH4, NiCl2•6H2O, MeOH (76%).
Scheme 7 Reagents: (a) CH3CH(NH2)CO2Me, C5H5N; then, P2O5
(80%); (b) succinimide (97%); (c) NaBH4; (d) MeOH, H+ (72%, 2 steps);
(e) CH3C·CSnBu3, BF3·OEt2 (92%); (f) diethylbenzene, reflux (50–55%);
(g) NaBH4, NiCl2, MeOH, 230 °C (73%).


































Noteworthy are the total syntheses of stenine (1), stemoamide
(9) and croomine (20) carried out by several groups which
definitively established the absolute configuration of these three
alkaloids. Considering that the Stemonaceae family comprises
more than 30 species and currently phytochemical investigation
is restricted to only 8 of them, the isolation of other Stemona
alkaloids can be expected in the future as well as continuing
progress towards the total syntheses of other representatives.
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